Bioorganic and medicinal chemistry letters (2020)
Update date:2022-08-02
Topics:
Li, Bo
Li, Wei
Li, Xue
Quan, Xu
Tan, Bin
Zhang, Xiaomeng
Zhao, Liwen
Zheng, Guochuang
TGF-β type I receptor (also known as activin-like kinase 5 or ALK5) plays a critical role in the progression of fibrotic diseases and tumor invasiveness and metastasis, as well. The development of small inhibitors targeting ALK5 has been validated as a potential therapeutic strategy for fibrotic diseases and cancer. Here, we developed various 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl) oxy) pyridine-2-yl) amino derivatives as ALK5 inhibitors. The optimization led to identification of potent and selective ALK5 inhibitors 12r. The compound 12r exhibited strong inhibitory activity both in vitro and in vivo, and pharmacokinetics study showed an oral bioavailability of 57.6percent. Thus, compound 12r may provide as new therapeutic option as ALK5 TGF-βR1 inhibitor.
View MoreJinzhou Jiutai Pharmaceutical Co.,Ltd
Contact:+86-0416-5179890
Address:No.41, Taianli, Taihe District, Jinzhou, Liaoning
SHANDONG QINGYUNCHANGXIN CHEMICAL SCIENCE-TECH CO.,LTD
Contact:86-21-60560171
Address:1689Donghuan Rade,Qingyun County, Dezhou City, Shandong,China
Zhengzhou Minzhong Pharmaceutical Co.,ltd
Contact:0086-371-65797115
Address:15/F,Jiangshan Bldg, NO.126 Huanghe Road,Zhengzhou, China
website:http://www.sagechem.com
Contact:+86-571-86818502
Address:Room C1301, New Youth Plaza, 8 Jia Shan Road, Hangzhou, China
Contact:86-27-84888681
Address:Wuhan economic & technology development zone
Doi:10.1016/j.tetlet.2006.09.122
(2006)Doi:10.1002/hlca.19850680203
(1985)Doi:10.1021/jm50001a003
(1985)Doi:10.1021/ja00333a044
(1984)Doi:10.1021/jo00196a018
(1984)Doi:10.1021/ja0640142
(2006)